Late Breaking Abstract - Lung deflation with Indacaterol/Glycopyrronium improves cardiac function in COPD patients: The CLAIM Study

Background: Cardiovascular diseases such as heart failure are common comorbidities of COPD and have a significant impact on morbidity and mortality. Lung hyperinflation detrimentally affects cardiac function in COPD patients. We hypothesized that lung deflation with the fixed-dose LABA/LAMA combination Indacaterol/Glycopyrronium (IND/GLY) would improve cardiac function in COPD patients. Methods: In this randomized, double-blind, single-center, placebo-controlled, 2 period cross-over trial, COPD patients with increased residual volume (RV > 135 % pred.) and without relevant cardiovascular disease were randomized to IND/GLY (110/50 µg q.d.) or placebo. Primary outcome was the change in left-ventricular end-diastolic volume (LVEDV) measured with MRI on day 14. Results: 62 patients were randomized, of which 57 completed both treatment phases. At day 14, IND/GLY treatment resulted in a significant increase of 10.27 ml in LVEDV (95% CI: 6.21 to 14.33, p Conclusion: Lung deflation with dual bronchodilation using IND/GLY substantially improved cardiac function with clinically relevant increase in right- and left-ventricular end-diastolic volumes and cardiac output in hyperinflated COPD patients.